Evidence map›Paper›PMID 21656330›Full record

Trial reportDiabetologia2011

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.

E L Lim, K G Hollingsworth, B S Aribisala, M J Chen, J C Mathers, R Taylor

6 registry-linked trialsOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Diabetologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 488 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
488citing papers in PubMed, 11 pooled it
61.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04271189 phase3completedstarted 2020, after this paper: background citation

A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.

Ran2020Enrolled108Registered outcomes10Posted comparisons0ConditionsNewly Diagnosed Type 2 DiabetesArmsMetformin-Sitagliptin-Empaglifozin-Pioglitazone, Standard of care
Open the trial in the graph
NCT01447524 nacompletednot on this map

Very Low Calorie Diet: a Quick Therapeutic Tool to Improve Beta Cell Function in Morbidly Obese Patients With Type 2 Diabetes Mellitus

TypeinterventionalSponsorUniversity of Rome Tor VergataRan2010 to 2011Enrolled14ConditionsMorbid Obesity, Type 2 Diabetes MellitusArmsVery Low Calorie Diet
NCT03536377 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Implementation of a Very Low Calorie Diet for Remission of Type 2 Diabetes in the Community

TypeinterventionalSponsorThe University of The West IndiesRan2019 to 2020Enrolled100ConditionsDiabetes Mellitus Type 2 in ObeseArmsvery low calorie liquid diet
NCT03900286 narecruitingnot on this mapstarted 2020, after this paper: background citation

Evaluating the Therapeutic Efficacy and Metabolic Impact of a Low Energy Diet (LED) in People With Familial Partial Lipodystrophy and Diabetes

TypeinterventionalSponsorCambridge University Hospitals NHS Foundation TrustRan2020 to 2025Enrolled20ConditionsLipodystrophy, Diabetes, Diet ModificationArmsTotal Dietary Replacement
NCT05275608 narecruitingnot on this mapstarted 2022, after this paper: background citation

Effects of Very Low Calorie Ketogenic Diet on Microbiota, Adipose Tissue and Immunitary Regulation: Pilot Study on Patients with Metabolic Syndrome

TypeinterventionalSponsorAzienda Ospedaliero Universitaria Maggiore della CaritaRan2022 to 2025Enrolled40ConditionsDiabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Obesity, Metabolic SyndromeArmsVLCKD diet with replacing meals, Hypocaloric mediterranean Diet
NCT07748949 narecruitingnot on this mapstarted 2026, after this paper: background citation

Effectiveness of a Low-Calorie Diet Combined With Intensive Lifestyle Intervention Using Integrated Personalized Diabetes Management for Achieving Diabetes Remission in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial

TypeinterventionalSponsorChulalongkorn UniversityRan2026 to 2027Enrolled54ConditionsType 2 Diabetes, Obesity & Overweight, Remission, Lifestyle InterventionArmsLow-calorie diet, Continous Glucose Monitor (CGM), Standard Care (in control arm), Personalized exercise program
3 · Its place in the literature

Who cites it

488 citing papers in PubMed, 11 syntheses or guidelines pooled it, 1,142 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

428 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

E L LimMagnetic Resonance Centre, Institute of Cellular Medicine, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, NE4 5PL, UK.
K G Hollingsworth
B S Aribisala
M J Chen
J C Mathers
R Taylor
Newcastle University · GB

Funding

Medical Research Council G0900686
6 · The paper itself

Abstract

aims/hypothesisType 2 diabetes is regarded as inevitably progressive, with irreversible beta cell failure. The hypothesis was tested that both beta cell failure and insulin resistance can be reversed by dietary restriction of energy intake.

methodsEleven people with type 2 diabetes (49.5 ± 2.5 years, BMI 33.6 ± 1.2 kg/m(2), nine male and two female) were studied before and after 1, 4 and 8 weeks of a 2.5 MJ (600 kcal)/day diet. Basal hepatic glucose output, hepatic and peripheral insulin sensitivity and beta cell function were measured. Pancreas and liver triacylglycerol content was measured using three-point Dixon magnetic resonance imaging. An age-, sex- and weight-matched group of eight non-diabetic participants was studied.

resultsAfter 1 week of restricted energy intake, fasting plasma glucose normalised in the diabetic group (from 9.2 ± 0.4 to 5.9 ± 0.4 mmol/l; p = 0.003). Insulin suppression of hepatic glucose output improved from 43 ± 4% to 74 ± 5% (p = 0.003 vs baseline; controls 68 ± 5%). Hepatic triacylglycerol content fell from 12.8 ± 2.4% in the diabetic group to 2.9 ± 0.2% by week 8 (p = 0.003). The first-phase insulin response increased during the study period (0.19 ± 0.02 to 0.46 ± 0.07 nmol min(-1) m(-2); p < 0.001) and approached control values (0.62 ± 0.15 nmol min(-1) m(-2); p = 0.42). Maximal insulin response became supranormal at 8 weeks (1.37 ± 0.27 vs controls 1.15 ± 0.18 nmol min(-1) m(-2)). Pancreatic triacylglycerol decreased from 8.0 ± 1.6% to 6.2 ± 1.1% (p = 0.03). CONCLUSIONS/

interpretationNormalisation of both beta cell function and hepatic insulin sensitivity in type 2 diabetes was achieved by dietary energy restriction alone. This was associated with decreased pancreatic and liver triacylglycerol stores. The abnormalities underlying type 2 diabetes are reversible by reducing dietary energy intake.

Indexed as

AdultAgedBlood GlucoseBody CompositionBody WeightDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansInsulin-Secreting CellsLiverMaleMiddle AgedPancreasTriglyceridesBlood GlucoseGlycated HemoglobinTriglycerides

Identifiers

PMID21656330
PMCPMC3168743
OpenAlexW2127283831

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.